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Abstract
C-type lectin-like receptor 2 (CLEC-2) plays a crucial role in different platelet-related 
physiological and pathological processes. It signals through a tyrosine kinase-mediated 
pathway that is highly dependent on the positive feedback exerted by the platelet-derived 
secondary mediators ADP and thromboxane A2 (TXA2). Here, we aimed to analyse the 
tyrosine phosphoproteome of platelets activated with the CLEC-2 agonist rhodocytin in order 
to identify relevant phosphorylated tyrosine residues (p-Tyr) and proteins involved in platelet 
activation downstream of this receptor. We identified 363 differentially p-Tyr residues, 
corresponding to the majority of proteins previously known to participate in CLEC-2 
signalling and also novel ones, including adaptors (e.g. DAPP1, Dok1/3, CASS4, Nck1/2); 
kinases/phosphatases (e.g. FAK1, FES, FGR, JAK2, SHIP2); and membrane proteins (e.g. 
G6F, JAM-A, PECAM-1, TLT-1). In order to elucidate the contribution of ADP and TXA2 at 
different points of the CLEC-2 signalling cascade, we evaluated p-Tyr levels of residues 
identified in the analysis and known to be essential for the catalytic activity of kinases Syk(p-
Tyr525+526) and Src(p-Tyr419), and for PLCγ2 activity (p-Tyr759). We demonstrated that Syk 
phosphorylation at Tyr525+526 also happens in the presence of ADP and TXA2 inhibitors, 
which is not the case for Src-pTyr419 and PLCγ2-pTyr759. Kinetics studies for the three 
phosphoproteins show some differences in the phosphorylation profile. Ca2+ mobilization 
assays confirmed the relevance of ADP and TXA2 for full CLEC-2-mediated platelet 































































activation. The present study provides significant insights into the intracellular events that 
take place following CLEC-2 activation in platelets, contributing to elucidate in detail the 
CLEC-2 signalosome. 
Key words: platelets, CLEC-2 signalling, tyrosine phosphoproteome
Summary Table
What is known on this topic:
 CLEC-2 plays a crucial role in maintaining vascular integrity, embryonic lymphatic 
vessel development, hematogenous metastasis and thrombus stabilization.
 CLEC-2 signals through a protein tyrosine-kinase-mediated pathway; the only 
endogenous ligand known so far is podoplanin.
What this paper adds:
 First tyrosine phosphoproteomic analysis of the CLEC-2 signalling cascade, analyzing 
in detail the impact of secondary mediators.
 Novel CLEC-2 signalling proteins and p-Tyr sites identified allowing a more complete 
and updated overview of the CLEC-2 signalosome.
 Kinetic studies show differences in the phosphorylation profiles of Syk-p-Tyr525+526, 
Src-pTyr419, and PLCγ2-pTyr759following CLEC-2 activation.
































































C-type lectin-like receptor 2 (CLEC-2) has been demonstrated to play a crucial role in 
maintaining vascular integrity1 and embryonic lymphatic vessel development2, and also 
participates in platelet-mediated hematogenous metastasis3.  CLEC-2 plays a minor role in 
haemostasis4, but contributes to thrombus stabilization under flow2. This latter process is a 
key step in the development of ischemic events associated with unwanted platelet activation.
CLEC-2 signals through a protein tyrosine-kinase-mediated pathway. The only 
endogenous agonist for CLEC-2 identified to date is podoplanin, a glycoprotein expressed on 
the surface of lymphatic endothelial cells, podocytes, type-I alveolar cells, and some tumour 
cells. In addition, rhodocytin, a protein isolated from the venom of the Malayan pit viper 
Calloselasma rhodostoma, is another CLEC-2 agonist, capable of inducing a potent platelet 
aggregation response following receptor engagement5,6.
The CLEC-2 signalling cascade starts with the tyrosine- phosphorylation of its 
immunoreceptor tyrosine-based activation motif (hemITAM), defined as a singular YxxL 
sequence within the cytoplasmic tail of the receptor. Cell signalling through ITAM motifs 
requires the presence of two YxxL sequences, which allo s receptor interaction with a Src 
homology 2 domain (SH2)-containing tyrosine-kinase. Therefore, bringing two hemITAM 
motifs in close vicinity through CLEC-2 dimerization is necessary for signal transduction. 
Once the hemITAM motifs of dimeric CLEC-2 have been phosphorylated, the tyrosine-kinase 
Syk interacts with the cytoplasmic tails of the dimer through its SH2 domains, reinforcing 
hemITAM phosphorylation and contributing to signal transduction. Subsequent biochemical 
events that take place in the intracellular space include the phosphorylation of the adapters 
LAT and SLP-76, and the activation of PLCγ2, leading to platelet aggregation7-10. The events 
taking place for primary phosphorylation of the hemITAM motifs are not yet completely 































































understood, but may involve the participation of Src-family tyrosine kinases (SFKs)11. 
Interestingly, CLEC-2 signalling in platelets has been found to be highly dependent in 
pathway reinforcement induced by the secondary mediators Adenosine diphosphate (ADP) 
and thromboxane A2 (TXA2), released from platelets upon activation and acting in an 
autocrine and paracrine manner12. Positive feedback by these secondary mediators is highly 
relevant in the amplification of the most proximal events that occur upon receptor activation, 
presumable through activation of SFKs and Syk that mediate CLEC-2 phosphorylation13.
Recently, we performed a gel-based proteomic analysis of the CLEC-2 signalling 
pathway14. This previous study was limited by the gel-based approach, which was far from 
being quantitative. Recent advances in mass spectrometry leading to confident identification 
of phosphorylation sites in complex protein samples, and the development of antibodies 
capable of recognizing specific phosphosites, have opened the path for more sensitive and 
quantitative proteomic analyses of signalling cascades in platelets. In this context, we have 
performed an extensive phosphotyrosine proteomic analysis of platelets stimulated through 
the CLEC-2 receptor in presence and absence of inhibitors of secondary mediators, in 
comparison with resting state, in order to identify new effectors in the signalling pathway 
coupled to this receptor and to elucidate the impact of secondary mediators in the tyrosine- 
phosphorylation response. In this way, it was possible to provide a much complete picture of 
the CLEC-2 signalosome, including identifying new proteins and mapping the precise 
phosphosites responsible for platelet activation through this receptor.
2. Materials and methods
A schematic representation of the methodology applied is shown in Figure 1. 































































2.1. Platelet isolation and activation
Fresh blood was obtained from healthy volunteers not under chronic medication, and not 
under anti-platelet drugs for the previous 10 days. The study was conducted according to the 
declaration of Helsinki, and with approval by the Galician Investigation Ethics Committee 
(code 2009-270). The age range of the donors was 22-51 years old; 50% of them were female. 
Blood was collected in coagulation 3.2% sodium citrate tubes (Vacuette), and samples were 
processed within the first 30 minutes after extraction.
Platelets isolation was following a well-established procedure that limits 
contamination with other blood cells and plasma proteins15. After washing steps, platelets 
were resuspended in HEPES-Tyrodes (134mM NaCl; 0.34mM Na2HPO4; 2.9 mM KCl; 
12mM NaHCO3; 20mM HEPES; 5mM glucose; 1mM MgCl2; pH 7.3) at a concentration of 8 
x108 platelets/ml and allowed to rest for 30 minutes at room temperature. 
From each healthy donor included in the proteomic study (two men and two women), 
we obtained platelet samples under three different stimulation conditions: basal (non- 
activated in absence of secondary mediators’ inhibitors), “Rhod” (rhodocytin- activated in 
absence of secondary mediators’ inhibitors), and “Rhod inh” (rhodocytin- activated in 
presence of secondary mediators’ inhibitors). We did not include a “Basal inh” condition in 
our proteomic analysis due to sample limitation issues to keep biological replicates and 
considering both types of basal samples elicit a similar tyr phosphoproteome profiles, with 
marginally lower phosphorylation levels in the presence of the inhibitors. Activations were 
performed for 5 minutes with 200nM rhodocytin at 37ºC and 1200rpm stirring in a Chrono-
log aggregometer. Optimal incubation times were based on previous data14 and the dose was 
adjusted in dose response experiments based on measuring the Tyr- phosphorylation protein 
profile by Western blotting (Supplementary Figure 1). All activations were performed after 
the addition of 9µM Integrilin® (GlaxoSmithKline), in order to avoid platelet aggregation and 































































the activation of the αIIbβ3 integrin signalling cascade. For inhibiting platelet stimulation by 
ADP and TXA2, 2U/ml of apyrase (ADPase that catalyses the hydrolysis of ADP), and 10µM 
of indomethacin (that inhibits COX-1 and thus the synthesis of TXA2), both from Sigma-
Aldrich, were added to the platelet suspension prior to CLEC-2 stimulation. 
For proteomic analysis, lysates were obtained by directly adding 2% SDS (final 
concentration) to 500 l of washed platelet suspensions. For validation analyses by Western 
blotting, lysates were obtained by supplementing platelet suspensions with an equal volume 
(500µl) of lysis buffer 2x (0.3M sodium chloride; 20mM Tris; 2mM EGTA; 2mM EDTA; 2% 
v/v NP-40; 10μg/ml aprotinin; 1μg/ml pepstatin; 10μg/ml leupeptin; 400μg/ml AEBFS; 5mM 
sodium orthovanadate; pH 7.5). 
2.2. Protein quantification and digestion for proteomic analysis
For proteomic analysis, four biological replicates were analysed per condition. Protein 
concentration in the sample was quantified with the micro BCATM protein assay kit (Pierce) 
following the manufacturer’s protocol. After that, 800µg of protein per sample were digested 
with trypsin following a large-scale filter aided sample preparation (LFASP) method  on 10 
kDa filters (AmiconTM Ultra-15, Millipore)16. Tryptic digests were dried and resuspended in 
700µl of IAP buffer (50mM MOPS pH 7.2; 10mM disodium phosphate; 50mM sodium 
chloride).
2.3. Phosphotyrosine peptide enrichment and LC-MS/MS analysis
Immunoaffinity enrichment of phosphotyrosine peptides was accomplished with PTMScan® 
Phospho-Tyrosine Rabbit mAb (P-Tyr-1000) Kit (Cell Signaling), as indicated in the 
Supplemental Methods. 































































Samples containing phospho-Tyr peptides were loaded in a nano Easy-nLC 1000 
chromatographic system (Proxeon), and mass spectra acquired on an LTQ-Orbitrap Velos 
(ThermoScientific). The spectra were searched against the human SwissProt database and 
validation of phosphorylation sites was performed by ptmRS and Percolator algorithms. 
Protein p-sites included in the analysis were those identified by at least two peptide spectrum 
matches (PSMs). Fold changes were calculated as the ratio of the number of PSMs that led to 
the identification of the corresponding protein p-site for the two compared conditions. Further 
details on the mass spec analysis and phosphosite identification can be found in the 
Supplemental Methods section.
2.4. Database search and data integration
Phosphosite Plus®17 database was scrutinized to find detailed information about Tyrosine-
phosphorylation sites detected in the proteins identified in the study. 
String©18 and PhosphoPath19 tools, powered by Cytoscape v3.720, were used to 
investigate potential interactions between differentially phosphorylated proteins, and to 
identify potential kinases responsible for the Tyr-phosphorylations detected in those proteins.
UniProtKB (UniProt Protein Knowledgebase)21  was consulted in order to obtain 
detailed information about relevant proteins identified in the study.
2.6. Ca2+ mobilization in vitro assays
Washed platelets (2x107 platelets/ml) from healthy donors were incubated with FLIPR 
Calcium 4 reagent (Molecular devices®), supplemented with Probenecid 0.07% and 
incubated for 1 hour at 37ºC in a 384-well transparent bottom plate. Inhibitors and agonists 
were dispensed by FDSS7000EX (Hamamatsu), automatically. Platelets were incubated for 































































10 minutes with 9M integrilin (eptifibatide) and, when necessary, with apyrase 2 U/ml, and 
indomethacin 10µM. After that, agonists (3µg/ml CRP, 0.75 U/ml thrombin, 100 nM or 200 
nM rhodocytin) were added to platelets. Changes in fluorescence were measured in real time 
for 15 minutes after the addition of the agonists and using emission and excitation wave 
lengths of 480nm and 540nm, respectively. 
2.7. Western blotting
For validation by Western blotting, four samples corresponding to four biological replicates 
from different cohorts of healthy donors were analysed per condition and experimental 
setting.
Proteins were precipitated from lysates in 20% trichloroacetic acid in acetone as 
previously described15, and protein pellets were resuspended in 50μl of sample buffer (65mM 
CHAPS, 5M urea, 2M thiourea, 0.15M NDSB-256, 30mM Tris, 1mM sodium vanadate, 
0.1mM sodium fluoride, and 1mM benzamidine). Protein quantitation was done with 
Coomassie Plus protein reagent (Thermo Scientific) following manufacturer’s protocol.
Protein separation by SDS-PAGE and subsequent immunoblotting were carried out as 
indicated in the Supplemental Methods. The following primary antibodies were used: rabbit 
anti-human p-PLCγ2 (Y759) (MAB7377, R&D systems) dilution 1/300; rabbit anti-p-Syk 
(Y525+Y526) (ab58575, Abcam) dilution 1/1000; rabbit anti-p-Src(Y418) (44660G, Fisher 
Scientific), dilution 1/1000; mouse anti-PLCγ2 (sc-5283, Santa Cruz Biotechnology) dilution 
1/500; mouse anti-Syk (sc-1240, Santa Cruz Biotechnology) dilution 1/1000; rabbit anti-Src 
pan (44-656G,Invitrogen), dilution 1/1000.
Further information on the statistical analysis can be found in the Supplemental 
Methods.
































































3.1. Tyrosine- phosphoproteome analysis of resting and CLEC-2 activated platelets. 
From the 12 samples analysed (corresponding to 4 biological replicates per condition), we 
identified a total number of 757 p-Tyr peptides, 466 p-Tyr residues and 264 proteins (Table 
1). More proteins, p-Tyr peptides, and pTyr sites were identified in “Rhod” samples 
(rhodocytin-activated platelets in absence of inhibitors of secondary mediators) (Table 1; 
Figure. 2A,B). Interestingly, from the 757 p-Tyr peptides identified, 258 were exclusively 
present in “Rhod” samples (Figure 2A). Considering the p-Tyr residues identified per 
condition, 458 were identified in “Rhod” samples, a number that decreased to 313 when 
platelets were activated in the presence of secondary mediators’ inhibitors (“Rhod inh”) 
(Figure 2B; Table 1). The overall results highlight the relevance of secondary mediators on 
achieving a robust intracellular tyrosine-phosphorylation response when platelets are activated 
through CLEC-2.  
Interestingly, our LC-MS/MS analysis led to the identification of p-Tyr residues in 20 
proteins that were not reported to undergo phosphorylation in those residues to date, some of 
them playing a relevant role in several intracellular signalling cascades, such as Btk, FES, 
Nck2, and ROCK2, and Talin, among others (Supplemental table 1).
 3.2. Phosphotyrosine fingerprint on CLEC-2 activated platelets: new signalling proteins 
identified.
As our data confirmed that the contribution of secondary mediators is essential for a powerful 
activation of the CLEC-2 coupled signalling pathway through tyrosine- phosphorylation, we 
performed our comparative analysis with the data obtained from “Rhod” and basal samples.
From the 235 proteins that were identified with at least one p-Tyr residue differentially 
regulated between the aforementioned conditions (Fold change ≥ 1.5), 21% are known to 































































participate in cytoskeleton remodelling process, and 58% are involved in signal transduction 
upon receptor activation (Figure 2C). From these signalling proteins, more than a half of 
them belong to protein kinases (23%) plus adaptors/scaffolds (30%) (Figure 2C). Table 2 
contains a selection of relevant signalling proteins and their p-Tyr residues identified in the 
study (fold change ≥ 1.5). In total, 363 differentially regulated p-Tyr residues were identified, 
encompassing almost all the proteins previously known to be key effectors in the CLEC-2 
signalling pathway, including: CLEC-2 itself, the adapters LAT, SLP-76, Vav, Grb2, ADAP, 
CrkL, Gads, Dok2, and SKAP2; the kinases Syk, the SFKs Lyn and Fyn, Btk, Csk, FER, and 
PIK3R1; the phosphatases SHP-1, SHP-2, SHIP1, and PTP1B; the phospholipase PLCγ2; and 
the receptors CD148, and G6b-B.
Furthermore, we identified differentially-regulated p-Tyr residues in a number of 
proteins that are relevant for intracellular signal transduction in platelets and other blood cell 
types. Here, we show for the first time that several of them are involved in the CLEC-2 
signalling cascade, including: the adaptors Gab1, DAPP1, Dok1, Dok3, CASS4, EFS, Pag1, 
Nck1 and Nck2; the kinases FAK1, FES, FGR, and JAK2, the phosphoinositide phosphatase 
SHIP2, and the membrane proteins G6F, JAM-A, PECAM-1, and TLT-1 (Table 2).
3.3. Secondary mediators (ADP and TXA2) are required for powerful tyrosine- 
phosphorylation response upon CLEC-2 activation.
Our phosphoproteomic data indicate secondary mediators are essential for a potent tyrosine- 
phosphorylation intracellular response mediated by CLEC-2 activation (Figure 2; Table 1). 
To further investigate this issue, we compared the fold changes (FC) obtained when 
comparing “Rhod” with basal samples, and “Rhod” with “Rhod inh” samples. We used this 
fold change comparison as an indirect measurement of the Tyr-phosphorylation levels 
between “Rhod inh” and resting platelets. Thus, when FC-values between both stimulation 































































conditions (“Rhod” vs. “Rhod inh”) are smaller than those obtained between “Rhod” and 
basal samples, we can conclude that rhodocytin stimulation itself is capable of altering Tyr- 
phosphorylation levels of the corresponding protein phosphorylation site. The smaller the 
“Rhod” vs. “Rhod inh” FC is, the higher the stimulation effect of Rhod inh. Therefore, from 
the 150 p-Tyr residues from relevant signalling proteins that we found differentially regulated 
(FC ≥ 1.5) in “Rhod” samples (Table 2), only 28 were directly regulated by rhodocytin- 
CLEC-2 engagement (FC Rhod/Rhod inh < FC Rhod/basal; FC Rhod/basal / FC Rhod/Rhod 
inh ≥ 1.5). Among these conditions, we identified p-Tyr residues for Syk, Gads, Dok2, SFKs, 
PLCγ2, SHP-1, and CASS4 (Supplemental table 2). 
3.4. CLEC-2 activation-mediated Ca2+ release is highly dependent on secondary 
mediators
In order to investigate more in detail the impact of secondary mediators in achieving full 
CLEC-2-mediated platelet activation, we developed a miniaturized calcium mobilization 
assay for platelets. All experiments were under non-aggregating conditions (with integrillin). 
Firstly, we checked a couple of Rhodocytin doses for platelet activation in presence and 
absence of secondary mediators inhibitors (apyrase and indomethacin). We demonstrated 
good levels of Ca2+ release with a 100 nM dose of Rhodocytin, similar to 200 nM. 
Importantly, Ca2+ release was drastically diminished in the presence of inhibitors (Figure 
3A). We next compared the latter effect with the impact of secondary mediators on platelet 
activation by the collagen receptor GPVI (activated with collagen-related peptide (CRP)), and 
PAR receptors (activated with thrombin). Such impact on Ca2+ release was minor compared 
to what happens in the case of CLEC-2 activation (Figure 3B). Finally, we explored the 
specific contribution of ADP and TXA2, individually, to CLEC-2 activation-mediated 
calcium release. Ca2+ release diminishes in the presence of apyrase or indomethacin, with a 































































higher impact of the former. Maximum inhibition of Ca2+ release following CLEC-2 
activation takes place when both inhibitors of secondary mediators are present at the same 
time (Figure 3C).
3.5. Contribution of secondary mediators to different steps essential for CLEC-2 
signalling 
In order to further elucidate the contribution of ADP and TXA2 at different points of the 
signalling pathway downstream of CLEC-2, we evaluated p-Tyr levels of residues that were 
identified in the analysis and are known to be essential for the catalytic activity of kinases Syk 
(p-Tyr525+526) and Src (p-Tyr419), and for PLCγ2 activity (p-Tyr759). To do so, we performed a 
western blot with protein samples obtained after activating the platelets in the presence or 
absence of apyrase and indomethacin under non aggregating conditions. In parallel, we just 
checked the aggregation profiles of platelets activated with Rhodcytin in the presence and 
absence of the secondary mediators inhibitors; as expected, the latter prevented aggregation 
(Figure 4A).
As it is shown in Figure 4B,C, phosphorylation of Syk on Tyr525/526, which is one of 
the primary events occurring upon CLEC-2 activation following hemITAM phosphorylation, 
is robustly increased in response to positive feedback by released ADP and TXA2. 
Nonetheless, CLEC-2 stimulation itself, in the presence of inhibitors of secondary mediators, 
led to a significant increase in phosphorylation of Syk Tyr525/526.
Robust phosphorylation of Src Tyr419, was also critically dependent on released ADP 
and TXA2. In this case, we also observed high levels of that phosphoprotein in resting (basal) 
platelets compared to the other two proteins analysed (Figure 4B,C). 
Finally, we also investigated the activation of PLCγ2, which enables Ca2+ release from 
intracellular stores and cytoskeleton remodelling process, so we evaluated its phosphorylation 































































on Tyr759. Optimal phosphorylation of PLCγ2 Tyr759 is only achieved when ADP and TXA2 
are not inhibited from exerting their positive feedback effects on CLEC-2 signalling (Figure 
4B,C).
One question that arises from the above data is whether the increase in tyrosine 
phosphorylation observed for the proteins validated is directly due to Rhodocytin-CLEC-2 
engagement with signalling reinforced by the secondary mediators’ positive feedback, or if 
such mediators could cause part of the increase by themselves. In order to clarify this issue, 
we activated platelets with ADP and arachidonic acid (AA), in comparison with Rhodocytin 
activation, in the absence of apyrase and indomethacin. Interestingly, ADP and AA are not 
able to induce an increase in the levels of Syk (p-Tyr525+526), Src (p-Tyr419), and PLCγ2 (p-
Tyr759), which confirms the differences observed in our analysis are mediated by CLEC-2 
activation (Fig. 5).
3.6. Tyrosine phosphorylation kinetic profiles show variations depending on the CLEC-2 
signalling protein analysed
To complete the signalling studies, we carried out a small scale kinetic analysis focusing on 
the three phosphoproteins mentioned above. As shown in Figure 6, tyrosine phosphorylation 
levels start to increase after 30 sec of platelet stimulation with 200 nM Rhodocytin and 
significant levels are still maintained after 5 minutes; however the kinetic profile is different 
depending on the protein. Thus, Syk, which plays a relevant role in early signalling events, is 
phosphorylated in Y525 and Y526 rapidly, reaching maximum levels after one minute and 
decreasing steadily after 90 sec. Regarding Src (p-Tyr419), basal levels are high compared with 
the other two proteins; nevertheless, there is an increase in phosphorylation levels following 
activation reaching the maximum after 1 min and maintaining such level for 3 min when it 































































starts to decrease gradually. Regarding PLCγ2 (p-Tyr759), maximum phosphorylation levels 
are also achieved between 1 and 3 min.
4. Discussion
The CLEC-2 receptor is known to mediate platelet activation through the stimulation of a 
phosphotyrosine signalling cascade that is triggered by phosphorylation of the tyrosine 
residue within its hemITAM5. In the present study, we aimed to analyse the phosphotyrosine 
proteome of CLEC-2-activated platelets. To do so, we performed an immunoaffinity 
enrichment of p-Tyr peptides in our samples, and we analysed them in an LTQ Orbitrap Velos 
mass spectrometer, an experimental tandem that allows high sensitivity on the identification 
of specific protein p-Tyr residues.
Results from our study emphasize the crucial synergism between the secondary 
mediators, ADP and TXA2, and CLEC-2 to induce a powerful activation of the receptor. To 
further explore this data, we evaluated the relevance of ADP and TXA2 in intracellular 
calcium release mediated by CLEC-2-Rhodocytin activation, and also by platelet activation 
with other agonists, such as CRP (GPVI agonist) and thrombin (PAR1/4 agonist). Our results 
clearly demonstrate the relevance of both ADP and TXA2 (together) to achieve full CLEC-2 
platelet activation, which does not happen in the case of GPVI or PAR1/4 activation. In 
addition, we also studied the phosphorylation levels of tyrosine sites that are crucial for the 
enzymatic activity of three proteins that are relevant for signal transduction upon CLEC-2 
activation: Syk p-Tyr525+526, Src p-Tyr419 and PLCγ2 p-Tyr759. Interestingly, we found that, 
although powerful platelet activation through the stimulatory effect of secondary mediators is 
essential for optimal Syk- kinase domain phosphorylation, rhodocytin stimulation of CLEC-2 
itself is sufficient to significantly increase Syk Tyr525+526 phosphorylation. In contrast, optimal 
phosphorylation of PLCγ2 Tyr759 is highly dependent on ADP and TXA2, indicating that the 































































initial steps of CLEC-2 signalling, including Syk phosphorylation, are not as dependent on 
ADP and TXA2 as downstream events. In resume, secondary mediators inhibitors are able to 
fully inhibit Src and  PLCγ2 tyrosine phosphorylation in the indicated residues, and can only 
partially inhibit Syk Tyr525+526.
To complement the above data, we also analysed the direct effect of ADP and AA to 
induce phosphorylation of Syk p-Tyr525+526, Src p-Tyr419 and PLCγ2 p-Tyr759, observing no 
effect, which indicates phosphorylation changes observed when activating platelets with 
rhodocytin in absence of apyrase and indomethacin are due to CLEC-2-activation and 
secondary mediators contribute only with a positive feedback to achieve full CLEC-2 tyrosine 
phosphorylation and signalling activation. Although it was previously suggested that the latter 
is mediated by Rac activation12, further research is needed to confirm the precise mechanism 
of this positive feedback in line with the present study. 
Complementary data on the three phosphoproteins mentioned above demonstrate 
differences in the kinetic profile of p-Tyr depending on the signalling protein analysed. For 
example, maximum phosphorylation levels of Syk on Tyr525+526 decrease faster than in the 
case of PLCγ2 Tyr759. The observed differences in the kinetic profile indicate that further 
kinetic studies by quantitative western blotting or proteomics are needed to have a more 
precise picture of the assembling of the CLEC-2 signalosome depicted in the present study.
Intriguingly, in the case of phosphorylation of Src Tyr419, which is located within the 
kinase domain responsible of Src-catalytic activity, the levels of basal samples were high 
compared to the other validated proteins, especially in the presence of secondary mediators 
(Figs. 4-6). This suggests the existence of a pool of active Src in platelets, reinforced by a 
basal release of secondary mediators. Further research is needed to explore this possibility; 
moreover, other SFKs besides Src, including Fyn, Lyn or Fgr, may contribute to signalling 
downstream of CLEC-2.































































Considering the above mentioned relevance of ADP and TXA2 in reinforcing CLEC-2 
signalling, as our aim was to obtain a broader picture of the biochemical events that are taking 
place in the signalling cascade downstream of CLEC-2 activation, we focused on the 
differentially regulated p-Tyr sites (FC ≥ 1.5) identified in “Rhod” samples (rhodocytin- 
activated in absence of inhibitors of secondary mediators) compared to unstimulated samples. 
We demonstrate differentially regulated p-Tyr residues for almost all the proteins known to 
participate in the CLEC-2 signalling pathway to date (Table 2). Interestingly, a number of 
those proteins were known to be phosphorylated upon CLEC-2 activation, but the specific 
tyrosine residues that undergo this modification were not described to date. Here, we have 
identified p-Tyr sites that are known to have great impact in signal transduction. CLEC-2 was 
found to be tyrosine phosphorylated on hemITAM motif -Tyr7-;5 phosphorylation of LAT 
Tyr220 was found to be up- regulated, which promotes its interaction with Grb2, Gads, and 
PIK3R122; Syk was phosphorylated at Tyr348 and Tyr352, both of which are essential for 
regulating Syk kinase activity, and at Tyr525 and Tyr526, required for catalytic activity23; the 
protein- tyrosine phosphatase SHP-1 was phosphorylated at Tyr536 and Tyr564, which have 
been implicated in regulating its activity  24; and CD148 was shown to be  phosphorylated on 
Tyr1311 and Tyr1320, previously reported to be  mediated by Src and Fyn25  and essential for 
SHP-1 interaction with CD148 SH2 domains. Moreover, the identification of several proteins 
tyrosine- phosphorylated on SH3, SH2, tyrosine- kinase, and phosphatase domains, as well as 
in ITIM motifs, highlights the potential relevance of the identified p-Tyr sites in mediating 
signal transduction upon CLEC-2 receptor activation (Table 2).
Furthermore, we have identified differentially regulated p-Tyr residues from proteins 
that have never been reported to play a role downstream of CLEC-2, but that are known to 
participate in regulating signal transduction in platelets and other blood cells. Some of these 
proteins have been described to interact and regulate the function of other known regulators of 































































CLEC-2 signalling. As a compendium of our proteomic data and the previous knowledge 
about protein interactions and functions, we have uncovered the more detailed picture of the 
CLEC-2 signalosome to date, represented in Figure 7, which includes key signalling proteins 
and their differentially regulated p-Tyr residues identified in our study. Interestingly, the set 
of proteins we show to be differentially- phosphorylated in our study suggests a delicate 
balance between stimulatory and inhibitory intracellular signals, which may be crucial for 
maintaining platelet activation without triggering an exacerbated response. Some of these 
novel phosphorylation sites and signalling proteins are likely to be clinically relevant, due to 
the potential interest of this receptor as a therapeutic target, since it seems to be crucial for 
thrombus stabilization, but not for haemostasis maintenance.   
Novel players on the CLEC-2 signalling cascade identified to be regulated by tyrosine- 
phosphorylation include the adapters Dok1 and Dok326, Nck1 and Nck227,28, and Crk- 
associated substrate (CAS) family members CASS4 and EFS29, among others (Table 2; 
Figure 7). Moreover, we report a number of up- regulated phosphorylated platelet kinases 
that were not previously described to participate in the CLEC-2 signalling cascade, but that 
are related to further signalling pathways, such as FAK, differentially phosphorylated at 
Tyr925, phosphorylation of which is mediated by FER allowing FAK interaction with Grb2 
and SHP-230; FES; and FGR31, among others (Table 2; Figure 7).
We also identified numerous p-Tyr residues differentially- regulated in proteins that 
are known to maintain platelet activation within physiological limits by exerting an inhibitory 
action during intracellular signalling processes. The most important effectors on regulating 
signal transduction upon ITAM-receptor activation are the immunoreceptor tyrosine-based 
inhibition motif (ITIM)-containing receptors. Tyrosine-phosphorylation of these domains 
provides docking sites for SH2 domain- containing phosphatases, such as SHIP1, SHP-1 and 
SHP-2, all of which were found to contain differentially regulated p-Tyr residues in our study 































































(Table 2; Figure 7), localizing the phosphatases in close proximity with ITAM-containing 
receptors that can then dephosphorylate and inactivate32. G6b-B is an ITIM-containing 
membrane protein that has been already reported to participate in CLEC-2 mediated 
signalling33,34, and that we found to be further phosphorylated on ITIM Tyr211 and Tyr237 upon 
rhodocytin stimulation. Moreover, we identified up-regulated tyrosine- phosphorylated 
residues for the other two known platelet ITIM-containing receptors, PECAM-1 and TLT-1. 
PECAM-1 was found to be phosphorylated on Tyr663, Tyr690, and Tyr713, the last two located 
on the ITIM domain of the protein, and both known to be phosphorylated by Lyn35. PECAM-
1 was reported to negatively regulate platelet GPVI-activation, as a feedback mechanism to 
limit thrombus growth, through the binding of its ITIM domains to SHP-236,37. Interestingly, 
PECAM-1 is thought to exert its inhibitory activity by an additional mechanism, consisting in 
the recruitment of PIK3R1 regulatory subunit of PI3K that we also found to be differentially 
tyrosine phosphorylated, through its interaction with SHP-2, negatively regulating the LAT 
signalosome by decreasing the interaction of LAT, Gab1 and PIK3R138. Gab1 is another 
protein that we are reporting to participate in the CLEC-2 signalling pathway for the first 
time, since we found differentially regulated p-Tyr residues of this protein following 
stimulation with rhodocytin. Gab1 is an adaptor protein that regulates signal transduction 
downstream of PI3K by directly interacting with this kinase. Finally, phosphorylation of 
Tyr245 in the atypical ITIM-containing receptor TLT-1 was found to be up-regulated in 
rhodocytin-stimulated platelets.  This residue was not previously reported to undergo 
phosphorylation, which may regulate downstream signalling39. Another kinase identified, 
Csk, phosphorylates the C-terminal tyrosine of SFKs inactivating them, a mechanism that is 
in part compensated by the phosphatase CD148, previously reported to participate in CLEC-2 
downstream signalling events40,41, and phosphorylation of which we found to be up-regulated 
in our proteomic analysis (Table 2; Figure 7). 































































Of the phosphatases found to be phosphorylated in rhodocytin-stimulated platelets, 
CD148, SHP-1, SHP-2, SHIP1, and PTP1B were previously reported to participate in the 
CLEC-2 signalling14,42-44. In addition, we also found p-Tyr residues within SHIP2, PTPRA, 
PTN18, and PTN12 (Table 2; Figure 7) to be up-regulated, suggesting these phosphatases 
may also contribute to the regulation of CLEC-2 signalling. Further, another protein that was 
reported to negatively regulate platelet signalling, and more precisely GPVI- mediated 
signalling downstream PI3K, is the adapter DAPP145. Interestingly, we found 
phosphorylation of Tyr139 within DAPP1 to be up-regulated, which is required for its 
interaction with PLCγ2 and protein function46,47.  
In conclusion, we have performed the most extensive tyrosine phosphoproteomic 
analysis of the CLEC-2 signalling pathway in platelets to date. We identified differentially 
regulated p-Tyr sites relevant for the activity of known as well as novel proteins in the CLEC-
2 signalling cascade. We also demonstrated a crucial role of AA and ADP (together) to 
achieve full CLEC-2-mediated platelet activation, and phosphorylation of relevant tyr sites in 
CLEC-2 signalling proteins. We also show that the kinetic profiles of phosphorylation of key 
tyrosine residues in some relevant CLEC-2 signalling proteins - such as Syk (Tyr525+526), Src 
(Tyr419) and PLCγ2 (Tyr759) - vary slightly depending on the precise phosphoprotein analysed, 
which provides clues on the role of each protein in the pathway. Overall, we believe that our 
study provides significant insights into the intracellular events that take place following 
CLEC-2 activation in platelets, contributing to elucidate in detail the CLEC-2 signalosome.
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Tables
Table 1. Results from LC-MS/MS analysis.
CONTITION P-TYR PEPTIDES P-TYR SITES P-TYR PROTEINS
Total 757 466 264
Basal 374 288 187
Rhod inh 421 313 198
Rhod 688 458 258
Rhod inh: rhodocytin- activated in presence of secondary mediators’ inhibitors; Rhod: 
rhodocytin- activated in absence of secondary mediators’ inhibitors.































































Table 2. Tyrosine- phosphorylation sites of relevant signalling proteins identified in “Rhod” vs. 
“Basal” samples with a fold change (FC) ≥ 1.5.
Uniprot code Protein names P-Site FC Relevant Domain
Adaptor/Scaffold
ABI1_HUMAN* Abl interactor 1 (ABI1) Y213 ∞
Y455 ∞ SH3
BANK1_HUMAN* B-cell scaffold protein with ankyrin repeats (BANK1) Y443 ∞
Y737 3.00
CASS4_HUMAN* Cas scaffolding protein family member 4 (CASS4) Y350 ∞
Y174 ∞
Y195 ∞





DAPP1_HUMAN* Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide (DAPP1) Y139 3.00
DOK1_HUMAN* Docking protein 1 (DOK1) Y377 ∞ Pro rich
Y296 ∞ Pro rich
Y362+Y377 ∞ Pro rich
Y409 3.50 Pro rich
Y449 1.50
DOK2_HUMAN Docking protein 2 (DOK2) Y139 ∞
Y402 ∞
DOK3_HUMAN* Docking protein 3 (DOK3) Y398 2.44 Pro rich
EFS_HUMAN* Embryonal Fyn-associated substrate (EFS) Y163 ∞ Pro rich
FYB1_HUMAN FYN-binding protein 1 (FYB1; ADAP; FYB; SLAP130) Y387 5.00
Y757 3.00 SH3
GAB1_HUMAN* GRB2-associated-binding protein 1 (GAB1) Y659 ∞
GRAP2_HUMAN GRB2-related adapter protein 2 (GRAP2; GADS) Y207 ∞
Y45 3.00 SH3
GRB2_HUMAN Growth factor receptor-bound protein 2 (GRB2) Y209 ∞ SH3
LAT_HUMAN Linker for activation of T-cells family member 1 (LAT) Y45 4.67
Y220 3.40
LCP2_HUMAN Lymphocyte cytosolic protein 2 (LCP2; SLP-76; SLP76) Y532 ∞
Y39 2.00
NCK1_HUMAN* Cytoplasmic protein NCK1 (NCK1; NCK) Y105 1.56































































Uniprot code Protein names P-Site FC Relevant Domain
Adaptor/Scaffold
NCK2_HUMAN* Cytoplasmic protein NCK2 (NCK2) Y50 ∞ SH3
Y251 ∞ SH3
Y110 2.91
NTAL_HUMAN* Linker for activation of T-cells family member 2 (LAT2; NTAL) Y136 ∞
Y58 ∞
PARD3_HUMAN* Partitioning defective 3 homolog (PARD3; PAR3) Y719 ∞
Y1080 4.00





REPS2_HUMAN* RalBP1-associated Eps domain-containing protein 2 (REPS2) Y558 ∞
SKAP2_HUMAN Src kinase-associated phosphoprotein 2 (SKAP2) Y169 ∞
Y334 2.00 SH3
Y151/Y152 -2.00
SPN90_HUMAN* NCK-interacting protein with SH3 domain (NCKIPSD; SPIN90) Y161 -∞
STAM2_HUMAN* Signal transducing adapter molecule 2 (STAM2) Y374 2.00 ITAM
VAV_HUMAN Proto-oncogene vav (VAV1; VAV) Y844 ∞
Y791 ∞ SH3
Y110 11.00
WASP_HUMAN* Wiskott-Aldrich syndrome protein (WAS) Y212 ∞
Y291 3.33
WIPF1_HUMAN* WAS/WASL-interacting protein family member 1 (WIPF1) Y455 ∞
WIPF2_HUMAN* WAS/WASL-interacting protein family member 2 (WIPF2) Y400 ∞
Kinase
ABL2_HUMAN* Tyrosine-protein kinase ABL2 (ABL2) Y439 ∞ Tyr- kinase
ACK1_HUMAN* Activated CDC42 kinase 1 (TNK2; ACK1) Y518 2.00
Y827 -1.67




CSK_HUMAN* Tyrosine-protein kinase CSK (CSK) Y18 ∞ SH3































































Uniprot code Protein names P-Site FC Relevant Domain
Kinase
FAK1_HUMAN* Focal adhesion kinase 1 (PTK2; FAK; FAK1) Y925 2.50
FER_HUMAN Tyrosine-protein kinase Fer (FER) Y402 ∞
Y714 3.33 Tyr- kinase
FES_HUMAN* Tyrosine-protein kinase Fes/Fps (FES; FPS) Y513 ∞
Y713 5.00 Tyr- kinase
FGR_HUMAN* Tyrosine-protein kinase Fgr (FGR; SRC2) Y208/Y209 ∞ SH2
FYN_HUMAN Tyrosine-protein kinase Fyn (FYN) Y213 ∞ SH2
JAK2_HUMAN* Tyrosine-protein kinase JAK2 (JAK2) Y570 1.83 Tyr- kinase
KALRN_HUMAN* Kalirin (KALRN) Y2265 4.00
KGP1_HUMAN* cGMP-dependent protein kinase 1 (PRKG1) Y336 ∞
KPCD_HUMAN Protein kinase C delta type (PRKCD) Y64 ∞
Y313 3.00
Y334 2.40




Y525+Y526 3.50 Tyr- kinase
Y526 1.50 Tyr- kinase
LYN_HUMAN Tyrosine-protein kinase Lyn (LYN) Y306 4.00 Kinase
MK01_HUMAN Mitogen-activated protein kinase 1 (MAPK1; ERK2) Y187 6.00 Tyr- kinase
MK03_HUMAN Mitogen-activated protein kinase 3 (MAPK3; ERK1) Y204 ∞ Kinase
MK08_HUMAN Mitogen-activated protein kinase 8 (MAPK8; JNK1) Y185 ∞ Kinase
MK09_HUMAN Mitogen-activated protein kinase 9 (MAPK9; JNK2) Y185 1.82 Kinase
MK12_HUMAN Mitogen-activated protein kinase 12 (MAPK12; ERK6) Y185 6.00 Kinase
MK14_HUMAN Mitogen-activated protein kinase 14 (MAPK14; CSBP) Y182 2.15 Kinase
MRCKB_HUMAN* Serine/threonine-protein kinase MRCK beta (CDC42BPB) Y1638 3.00
P85A_HUMAN Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1; GRB1) Y467 2.00
PI4KA_HUMAN* Phosphatidylinositol 4-kinase alpha (PI4KA; PIK4) Y1154 -4.00
ROCK2_HUMAN* Rho-associated protein kinase 2 (ROCK2) Y722 5.00
Y450 5.00
SRC_HUMAN Proto-oncogene tyrosine-protein kinase Src (SRC; SRC1) Y187 -2.00 SH2































































Uniprot code Protein names P-Site FC Domain
Phosphatase
PTN1_HUMAN Tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP1B) Y46 4.00 Phosphatase
PTN11_HUMAN Tyrosine-protein phosphatase non-receptor type 11 (PTPN11; SHP-2) Y584 1.57
PTN12_HUMAN* Tyrosine-protein phosphatase non-receptor type 12 (PTPN12; PTPG1) Y64 ∞ Phosphatase
PTN18_HUMAN* Tyrosine-protein phosphatase non-receptor type 18 (PTPN18) Y426 ∞
Y389 2.50




SHIP1_HUMAN Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (INPP5D; SHIP; SHIP1) Y1022 ∞ Pro rich










CLC1B_HUMAN C-type lectin domain family 1 member B (CLEC1B; CLEC2) Y7 ∞ ITAM
FCERG_HUMAN* High affinity immunoglobulin epsilon receptor subunit gamma (FCER1G) Y58 2.00 ITAM
FCG2A_HUMAN* Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) Y304 3.00
G6B_HUMAN Megakaryocyte and platelet inhibitory receptor G6b (MPIG6B; G6B; G6B-B) Y211 4.33 ITIM
Y237 2.00 ITIM
PTPRA_HUMAN* Receptor-type tyrosine-protein phosphatase alpha (PTPRA; PTPA) Y798 2.00
PTPRJ_HUMAN Receptor-type tyrosine-protein phosphatase eta (PTPRJ; CD148) Y1311+Y1320 ∞
Y1311 9.00
JAM1_HUMAN* Junctional adhesion molecule A (JAM-A) Y280 -3.00
TRML1_HUMAN* Trem-like transcript 1 protein (TLT-1) Y245 3.06 Pro rich































































Uniprot code Protein names P-Site FC Domain
Small GTPase
RAB13_HUMAN* Ras-related protein Rab-13 (RAB13) Y5 ∞
RAB1B_HUMAN* Ras-related protein Rab-1B (RAB1B) Y5 ∞
RAN_HUMAN* GTP-binding nuclear protein Ran (RAN) Y39 1.50
GAP
ARAP1_HUMAN* Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 (ARAP1) Y737 3.50
IQGA2_HUMAN* Ras GTPase-activating-like protein IQGAP2 (IQGAP2) Y93 ∞
RASA1_HUMAN* Ras GTPase-activating protein 1 (RASA1) Y615 2.00
RASA3_HUMAN* Ras GTPase-activating protein 3 (RASA3) Y66 ∞
RHG18_HUMAN* Rho GTPase-activating protein 18 (ARHGAP18) Y41 4.00
RHG35_HUMAN* Rho GTPase-activating protein 35 (ARHGAP35) Y1087 ∞
Y1105 1.75
GDI
GDIR2_HUMAN* Rho GDP-dissociation inhibitor 2 (ARHGDIB) Y130 -∞
Y24 ∞
GEF










GRP2_HUMAN* RAS guanyl-releasing protein 2 (RASGRP2) Y523 -2.00
Other
LY66F_HUMAN* Lymphocyte antigen 6 complex locus protein G6f (LY6G6F; G6F) Y281 4.50
PECA1_HUMAN* Platelet endothelial cell adhesion molecule (PECAM-1) Y663 3.67
Y690 ∞ ITIM
A positive fold change indicates that the variation is favourable to “Rhod” samples (rhodocytin- activated in 
absence of secondary mediators’ inhibitors), and a negative fold change indicates that the variation is 
favourable to basal samples. Fold changes were calculated as the quotient of the total number of PSMs that led 
to the identification of the protein p-site. GAP: GTPase-activating protein; GDI: GDP dissociation inhibitor; 
GEF: Guanine nucleotide exchange factor. ∞ means infinity.
* Means that the protein was not previously reported to participate in CLEC-2 signalling pathway.
































































Figure 1. Experimental workflow. Schematic representation of the methodology 
applied and the equipment employed in this study.
Figure 2. P-Tyr peptides, and p-Tyr sites identified by LC-MS/MS. Function of 
proteins with differentially regulated p-Tyr sites in CLEC-2-activated platelets. 
Venn diagrams represent the total number of p-Tyr peptides (A), and the corresponding 
p-Tyr sites (B), that were identified in each analysed condition. C) Functions of proteins 
that were identified with differentially regulated p-Tyr sites in CLEC-2-activated vs. 
basal platelets. Charts represent protein functions distribution (FC ≥ 1.5).
Figure 3. Ca2+ mobilization following CLEC-2 activation is dependent on 
secondary mediators. A) Secondary mediators play a fundamental role in CLEC-2-
mediated Ca2+ release induced by platelet activation with Rhodcytin. B) Secondary 
mediators are needed for a full platelet activation induced by Rhodocytin, in contrast 
with what occurs in the case of platelet activation with CRP or thrombin. C) Both ADP 
and TXA2 together are needed for full CLEC-2 activation. Rhod, Rhodocytin; CRP, 
collagen-related peptide; THR, thrombin. All measurements were done in triplicate 
(biological replicates). For further experimental details please see section 2.6.
Figure 4. Contribution of ADP and TXA2 to phosphorylation of relevant tyrosine 
residues in Src, Syk, and PLC2 downstream of CLEC-2. A) Aggregation profile of 
platelets stimulated with 200nM rhodocytin in absence and presence of secondary 
mediators inhibitors (2U/mL apyrase and indomethacin 10µM). Representative western 
blot images (B), and densitometry graphs (C), representing tyrosine phosphorylation 
levels of Src p-Tyr419, Syk p-Tyr525+526, and PLCγ2 p-Tyr759. ** p< 0.01 (RM one way 































































Anova with Tukey´s post-hoc multiple comparisons). Experiments were done with 
samples obtained from 4 different healthy donors (biological replicates).
Figure 5. ADP and arachidonic acid do not induce tyrosine phosphorylation of Src, 
Syk, and PLC2 in the same residues CLEC-2 activation does. A) Aggregation 
profile of platelets stimulated with 200nM rhodocytin, 10 µM ADP, and 100 µM AA.  
Representative western blot images (B) and densitometry graphs (C) showing tyrosine 
phosphorylation levels of Src p-Tyr419, Syk p-Tyr525+526, and PLCγ2 p-Tyr759 in 
response to Rhodocytin and AA+ADP. Comparisons were between each stimulus and 
its respective control. ** p< 0.01 (paired Student´s t-test). Experiments were done with 
samples obtained from 4 different healthy donors (biological replicates).
Figure 6. Kinetic studies on essential tyrosine residues in Src, Syk, and PLC2 
downstream of CLEC-2 point out differences in the phosphorylation pattern. 
Representative western blot images (A), and densitometry graphs (B) showing tyrosine 
phosphorylation profiles of Src p-Tyr419, Syk p-Tyr525+526, and PLCγ2 p-Tyr759 
following platelet activation with rhodocytin for 30s, 60s, 120s, 180s and 300s. For 
statistics, comparisons were always between each activation time point and basal 
(control platelets). *p<0.05, ** p < 0.01, and *** p < 0.001 (paired Student´s t-test). 
Experiments were done with samples obtained from 4 different healthy donors 
(biological replicates).
Figure 7. The CLEC-2 signalling pathway in platelets: solving the puzzle. New 
proposal for the platelet CLEC-2 signalling cascade in which relevant signalling 
proteins and their corresponding differentially regulated p-Tyr sites identified in the 
present study are highlighted. This figure only includes those Tyr residues that were 
identified as differentially regulated in the present proteomic study (Fold change ≥ 1.5). 































































Further information on how the information to build the figure was retrieved can be 
found in section 2.4.
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Abstract
C-type lectin-like receptor 2 (CLEC-2) plays a crucial role in different platelet-related 
physiological and pathological processes. It signals through a tyrosine kinase-mediated 
pathway that is highly dependent on the positive feedback exerted by the platelet-derived 
secondary mediators ADP and thromboxane A2 (TXA2). Here, we aimed to analyse the 
tyrosine phosphoproteome of platelets activated with the CLEC-2 agonist rhodocytin in order 
to identify relevant phosphorylated tyrosine residues (p-Tyr) and proteins involved in platelet 
activation downstream of this receptor. We identified 363 differentially p-Tyr residues, 
corresponding to the majority of proteins previously known to participate in CLEC-2 
signalling and also novel ones, including adaptors (e.g. DAPP1, Dok1/3, CASS4, Nck1/2); 
kinases/phosphatases (e.g. FAK1, FES, FGR, JAK2, SHIP2); and membrane proteins (e.g. 
G6F, JAM-A, PECAM-1, TLT-1). In order to elucidate the contribution of ADP and TXA2 at 
different points of the CLEC-2 signalling cascade, we evaluated p-Tyr levels of residues 
identified in the analysis and known to be essential for the catalytic activity of kinases Syk(p-
Tyr525+526) and Src(p-Tyr419), and for PLCγ2 activity (p-Tyr759). We demonstrated that Syk 
phosphorylation at Tyr525+526 also happens in the presence of ADP and TXA2 inhibitors, 
which is not the case for Src-pTyr419 and PLCγ2-pTyr759. Kinetics studies for the three 
phosphoproteins show some differences in the phosphorylation profile. Ca2+ mobilization 
assays confirmed the relevance of ADP and TXA2 for full CLEC-2-mediated platelet 































































activation. The present study provides significant insights into the intracellular events that 
take place following CLEC-2 activation in platelets, contributing to elucidate in detail the 
CLEC-2 signalosome. 
Key words: platelets, CLEC-2 signalling, tyrosine phosphoproteome
Summary Table
What is known on this topic:
 CLEC-2 plays a crucial role in maintaining vascular integrity, embryonic lymphatic 
vessel development, hematogenous metastasis and thrombus stabilization.
 CLEC-2 signals through a protein tyrosine-kinase-mediated pathway; the only 
endogenous ligand known so far is podoplanin.
What this paper adds:
 First tyrosine phosphoproteomic analysis of the CLEC-2 signalling cascade, analyzing 
in detail the impact of secondary mediators.
 Novel CLEC-2 signalling proteins and p-Tyr sites identified allowing a more complete 
and updated overview of the CLEC-2 signalosome.
 Kinetic studies show differences in the phosphorylation profiles of Syk-p-Tyr525+526, 
Src-pTyr419, and PLCγ2-pTyr759following CLEC-2 activation.
































































C-type lectin-like receptor 2 (CLEC-2) has been demonstrated to play a crucial role in 
maintaining vascular integrity1 and embryonic lymphatic vessel development2, and also 
participates in platelet-mediated hematogenous metastasis3.  CLEC-2 plays a minor role in 
haemostasis4, but contributes to thrombus stabilization under flow2. This latter process is a 
key step in the development of ischemic events associated with unwanted platelet activation.
CLEC-2 signals through a protein tyrosine-kinase-mediated pathway. The only 
endogenous agonist for CLEC-2 identified to date is podoplanin, a glycoprotein expressed on 
the surface of lymphatic endothelial cells, podocytes, type-I alveolar cells, and some tumour 
cells. In addition, rhodocytin, a protein isolated from the venom of the Malayan pit viper 
Calloselasma rhodostoma, is another CLEC-2 agonist, capable of inducing a potent platelet 
aggregation response following receptor engagement5,6.
The CLEC-2 signalling cascade starts with the tyrosine- phosphorylation of its 
immunoreceptor tyrosine-based activation motif (hemITAM), defined as a singular YxxL 
sequence within the cytoplasmic tail of the receptor. Cell signalling through ITAM motifs 
requires the presence of two YxxL sequences, which allo s receptor interaction with a Src 
homology 2 domain (SH2)-containing tyrosine-kinase. Therefore, bringing two hemITAM 
motifs in close vicinity through CLEC-2 dimerization is necessary for signal transduction. 
Once the hemITAM motifs of dimeric CLEC-2 have been phosphorylated, the tyrosine-kinase 
Syk interacts with the cytoplasmic tails of the dimer through its SH2 domains, reinforcing 
hemITAM phosphorylation and contributing to signal transduction. Subsequent biochemical 
events that take place in the intracellular space include the phosphorylation of the adapters 
LAT and SLP-76, and the activation of PLCγ2, leading to platelet aggregation7-10. The events 
taking place for primary phosphorylation of the hemITAM motifs are not yet completely 































































understood, but may involve the participation of Src-family tyrosine kinases (SFKs)11. 
Interestingly, CLEC-2 signalling in platelets has been found to be highly dependent in 
pathway reinforcement induced by the secondary mediators Adenosine diphosphate (ADP) 
and thromboxane A2 (TXA2), released from platelets upon activation and acting in an 
autocrine and paracrine manner12. Positive feedback by these secondary mediators is highly 
relevant in the amplification of the most proximal events that occur upon receptor activation, 
presumable through activation of SFKs and Syk that mediate CLEC-2 phosphorylation13.
Recently, we performed a gel-based proteomic analysis of the CLEC-2 signalling 
pathway14. This previous study was limited by the gel-based approach, which was far from 
being quantitative. Recent advances in mass spectrometry leading to confident identification 
of phosphorylation sites in complex protein samples, and the development of antibodies 
capable of recognizing specific phosphosites, have opened the path for more sensitive and 
quantitative proteomic analyses of signalling cascades in platelets. In this context, we have 
performed an extensive phosphotyrosine proteomic analysis of platelets stimulated through 
the CLEC-2 receptor in presence and absence of inhibitors of secondary mediators, in 
comparison with resting state, in order to identify new effectors in the signalling pathway 
coupled to this receptor and to elucidate the impact of secondary mediators in the tyrosine- 
phosphorylation response. In this way, it was possible to provide a much complete picture of 
the CLEC-2 signalosome, including identifying new proteins and mapping the precise 
phosphosites responsible for platelet activation through this receptor.
2. Materials and methods
A schematic representation of the methodology applied is shown in Figure 1. 































































2.1. Platelet isolation and activation
Fresh blood was obtained from healthy volunteers not under chronic medication, and not 
under anti-platelet drugs for the previous 10 days. The study was conducted according to the 
declaration of Helsinki, and with approval by the Galician Investigation Ethics Committee 
(code 2009-270). The age range of the donors was 22-51 years old; 50% of them were female. 
Blood was collected in coagulation 3.2% sodium citrate tubes (Vacuette), and samples were 
processed within the first 30 minutes after extraction.
Platelets isolation was following a well-established procedure that limits 
contamination with other blood cells and plasma proteins15. After washing steps, platelets 
were resuspended in HEPES-Tyrodes (134mM NaCl; 0.34mM Na2HPO4; 2.9 mM KCl; 
12mM NaHCO3; 20mM HEPES; 5mM glucose; 1mM MgCl2; pH 7.3) at a concentration of 8 
x108 platelets/ml and allowed to rest for 30 minutes at room temperature. 
From each healthy donor included in the proteomic study (two men and two women), 
we obtained platelet samples under three different stimulation conditions: basal (non- 
activated in absence of secondary mediators’ inhibitors), “Rhod” (rhodocytin- activated in 
absence of secondary mediators’ inhibitors), and “Rhod inh” (rhodocytin- activated in 
presence of secondary mediators’ inhibitors). We did not include a “Basal inh” condition in 
our proteomic analysis due to sample limitation issues to keep biological replicates and 
considering both types of basal samples elicit a similar tyr phosphoproteome profiles, with 
marginally lower phosphorylation levels in the presence of the inhibitors. Activations were 
performed for 5 minutes with 200nM rhodocytin at 37ºC and 1200rpm stirring in a Chrono-
log aggregometer. Optimal incubation times were based on previous data14 and the dose was 
adjusted in dose response experiments based on measuring the Tyr- phosphorylation protein 
profile by Western blotting (Supplementary Figure 1). All activations were performed after 
the addition of 9µM Integrilin® (GlaxoSmithKline), in order to avoid platelet aggregation and 































































the activation of the αIIbβ3 integrin signalling cascade. For inhibiting platelet stimulation by 
ADP and TXA2, 2U/ml of apyrase (ADPase that catalyses the hydrolysis of ADP), and 10µM 
of indomethacin (that inhibits COX-1 and thus the synthesis of TXA2), both from Sigma-
Aldrich, were added to the platelet suspension prior to CLEC-2 stimulation. 
For proteomic analysis, lysates were obtained by directly adding 2% SDS (final 
concentration) to 500 l of washed platelet suspensions. For validation analyses by Western 
blotting, lysates were obtained by supplementing platelet suspensions with an equal volume 
(500µl) of lysis buffer 2x (0.3M sodium chloride; 20mM Tris; 2mM EGTA; 2mM EDTA; 2% 
v/v NP-40; 10μg/ml aprotinin; 1μg/ml pepstatin; 10μg/ml leupeptin; 400μg/ml AEBFS; 5mM 
sodium orthovanadate; pH 7.5). 
2.2. Protein quantification and digestion for proteomic analysis
For proteomic analysis, four biological replicates were analysed per condition. Protein 
concentration in the sample was quantified with the micro BCATM protein assay kit (Pierce) 
following the manufacturer’s protocol. After that, 800µg of protein per sample were digested 
with trypsin following a large-scale filter aided sample preparation (LFASP) method  on 10 
kDa filters (AmiconTM Ultra-15, Millipore)16. Tryptic digests were dried and resuspended in 
700µl of IAP buffer (50mM MOPS pH 7.2; 10mM disodium phosphate; 50mM sodium 
chloride).
2.3. Phosphotyrosine peptide enrichment and LC-MS/MS analysis
Immunoaffinity enrichment of phosphotyrosine peptides was accomplished with PTMScan® 
Phospho-Tyrosine Rabbit mAb (P-Tyr-1000) Kit (Cell Signaling), as indicated in the 
Supplemental Methods. 































































Samples containing phospho-Tyr peptides were loaded in a nano Easy-nLC 1000 
chromatographic system (Proxeon), and mass spectra acquired on an LTQ-Orbitrap Velos 
(ThermoScientific). The spectra were searched against the human SwissProt database and 
validation of phosphorylation sites was performed by ptmRS and Percolator algorithms. 
Protein p-sites included in the analysis were those identified by at least two peptide spectrum 
matches (PSMs). Fold changes were calculated as the ratio of the number of PSMs that led to 
the identification of the corresponding protein p-site for the two compared conditions. Further 
details on the mass spec analysis and phosphosite identification can be found in the 
Supplemental Methods section.
2.4. Database search and data integration
Phosphosite Plus®17 database was scrutinized to find detailed information about Tyrosine-
phosphorylation sites detected in the proteins identified in the study. 
String©18 and PhosphoPath19 tools, powered by Cytoscape v3.720, were used to 
investigate potential interactions between differentially phosphorylated proteins, and to 
identify potential kinases responsible for the Tyr-phosphorylations detected in those proteins.
UniProtKB (UniProt Protein Knowledgebase)21  was consulted in order to obtain 
detailed information about relevant proteins identified in the study.
2.6. Ca2+ mobilization in vitro assays
Washed platelets (2x107 platelets/ml) from healthy donors were incubated with FLIPR 
Calcium 4 reagent (Molecular devices®), supplemented with Probenecid 0.07% and 
incubated for 1 hour at 37ºC in a 384-well transparent bottom plate. Inhibitors and agonists 
were dispensed by FDSS7000EX (Hamamatsu), automatically. Platelets were incubated for 































































10 minutes with 9M integrilin (eptifibatide) and, when necessary, with apyrase 2 U/ml, and 
indomethacin 10µM. After that, agonists (3µg/ml CRP, 0.75 U/ml thrombin, 100 nM or 200 
nM rhodocytin) were added to platelets. Changes in fluorescence were measured in real time 
for 15 minutes after the addition of the agonists and using emission and excitation wave 
lengths of 480nm and 540nm, respectively. 
2.7. Western blotting
For validation by Western blotting, four samples corresponding to four biological replicates 
from different cohorts of healthy donors were analysed per condition and experimental 
setting.
Proteins were precipitated from lysates in 20% trichloroacetic acid in acetone as 
previously described15, and protein pellets were resuspended in 50μl of sample buffer (65mM 
CHAPS, 5M urea, 2M thiourea, 0.15M NDSB-256, 30mM Tris, 1mM sodium vanadate, 
0.1mM sodium fluoride, and 1mM benzamidine). Protein quantitation was done with 
Coomassie Plus protein reagent (Thermo Scientific) following manufacturer’s protocol.
Protein separation by SDS-PAGE and subsequent immunoblotting were carried out as 
indicated in the Supplemental Methods. The following primary antibodies were used: rabbit 
anti-human p-PLCγ2 (Y759) (MAB7377, R&D systems) dilution 1/300; rabbit anti-p-Syk 
(Y525+Y526) (ab58575, Abcam) dilution 1/1000; rabbit anti-p-Src(Y418) (44660G, Fisher 
Scientific), dilution 1/1000; mouse anti-PLCγ2 (sc-5283, Santa Cruz Biotechnology) dilution 
1/500; mouse anti-Syk (sc-1240, Santa Cruz Biotechnology) dilution 1/1000; rabbit anti-Src 
pan (44-656G,Invitrogen), dilution 1/1000.
Further information on the statistical analysis can be found in the Supplemental 
Methods.
































































3.1. Tyrosine- phosphoproteome analysis of resting and CLEC-2 activated platelets. 
From the 12 samples analysed (corresponding to 4 biological replicates per condition), we 
identified a total number of 757 p-Tyr peptides, 466 p-Tyr residues and 264 proteins (Table 
1). More proteins, p-Tyr peptides, and pTyr sites were identified in “Rhod” samples 
(rhodocytin-activated platelets in absence of inhibitors of secondary mediators) (Table 1; 
Figure. 2A,B). Interestingly, from the 757 p-Tyr peptides identified, 258 were exclusively 
present in “Rhod” samples (Figure 2A). Considering the p-Tyr residues identified per 
condition, 458 were identified in “Rhod” samples, a number that decreased to 313 when 
platelets were activated in the presence of secondary mediators’ inhibitors (“Rhod inh”) 
(Figure 2B; Table 1). The overall results highlight the relevance of secondary mediators on 
achieving a robust intracellular tyrosine-phosphorylation response when platelets are activated 
through CLEC-2.  
Interestingly, our LC-MS/MS analysis led to the identification of p-Tyr residues in 20 
proteins that were not reported to undergo phosphorylation in those residues to date, some of 
them playing a relevant role in several intracellular signalling cascades, such as Btk, FES, 
Nck2, and ROCK2, and Talin, among others (Supplemental table 1).
 3.2. Phosphotyrosine fingerprint on CLEC-2 activated platelets: new signalling proteins 
identified.
As our data confirmed that the contribution of secondary mediators is essential for a powerful 
activation of the CLEC-2 coupled signalling pathway through tyrosine- phosphorylation, we 
performed our comparative analysis with the data obtained from “Rhod” and basal samples.
From the 235 proteins that were identified with at least one p-Tyr residue differentially 
regulated between the aforementioned conditions (Fold change ≥ 1.5), 21% are known to 































































participate in cytoskeleton remodelling process, and 58% are involved in signal transduction 
upon receptor activation (Figure 2C). From these signalling proteins, more than a half of 
them belong to protein kinases (23%) plus adaptors/scaffolds (30%) (Figure 2C). Table 2 
contains a selection of relevant signalling proteins and their p-Tyr residues identified in the 
study (fold change ≥ 1.5). In total, 363 differentially regulated p-Tyr residues were identified, 
encompassing almost all the proteins previously known to be key effectors in the CLEC-2 
signalling pathway, including: CLEC-2 itself, the adapters LAT, SLP-76, Vav, Grb2, ADAP, 
CrkL, Gads, Dok2, and SKAP2; the kinases Syk, the SFKs Lyn and Fyn, Btk, Csk, FER, and 
PIK3R1; the phosphatases SHP-1, SHP-2, SHIP1, and PTP1B; the phospholipase PLCγ2; and 
the receptors CD148, and G6b-B.
Furthermore, we identified differentially-regulated p-Tyr residues in a number of 
proteins that are relevant for intracellular signal transduction in platelets and other blood cell 
types. Here, we show for the first time that several of them are involved in the CLEC-2 
signalling cascade, including: the adaptors Gab1, DAPP1, Dok1, Dok3, CASS4, EFS, Pag1, 
Nck1 and Nck2; the kinases FAK1, FES, FGR, and JAK2, the phosphoinositide phosphatase 
SHIP2, and the membrane proteins G6F, JAM-A, PECAM-1, and TLT-1 (Table 2).
3.3. Secondary mediators (ADP and TXA2) are required for powerful tyrosine- 
phosphorylation response upon CLEC-2 activation.
Our phosphoproteomic data indicate secondary mediators are essential for a potent tyrosine- 
phosphorylation intracellular response mediated by CLEC-2 activation (Figure 2; Table 1). 
To further investigate this issue, we compared the fold changes (FC) obtained when 
comparing “Rhod” with basal samples, and “Rhod” with “Rhod inh” samples. We used this 
fold change comparison as an indirect measurement of the Tyr-phosphorylation levels 
between “Rhod inh” and resting platelets. Thus, when FC-values between both stimulation 































































conditions (“Rhod” vs. “Rhod inh”) are smaller than those obtained between “Rhod” and 
basal samples, we can conclude that rhodocytin stimulation itself is capable of altering Tyr- 
phosphorylation levels of the corresponding protein phosphorylation site. The smaller the 
“Rhod” vs. “Rhod inh” FC is, the higher the stimulation effect of Rhod inh. Therefore, from 
the 150 p-Tyr residues from relevant signalling proteins that we found differentially regulated 
(FC ≥ 1.5) in “Rhod” samples (Table 2), only 28 were directly regulated by rhodocytin- 
CLEC-2 engagement (FC Rhod/Rhod inh < FC Rhod/basal; FC Rhod/basal / FC Rhod/Rhod 
inh ≥ 1.5). Among these conditions, we identified p-Tyr residues for Syk, Gads, Dok2, SFKs, 
PLCγ2, SHP-1, and CASS4 (Supplemental table 2). 
3.4. CLEC-2 activation-mediated Ca2+ release is highly dependent on secondary 
mediators
In order to investigate more in detail the impact of secondary mediators in achieving full 
CLEC-2-mediated platelet activation, we developed a miniaturized calcium mobilization 
assay for platelets. All experiments were under non-aggregating conditions (with integrillin). 
Firstly, we checked a couple of Rhodocytin doses for platelet activation in presence and 
absence of secondary mediators inhibitors (apyrase and indomethacin). We demonstrated 
good levels of Ca2+ release with a 100 nM dose of Rhodocytin, similar to 200 nM. 
Importantly, Ca2+ release was drastically diminished in the presence of inhibitors (Figure 
3A). We next compared the latter effect with the impact of secondary mediators on platelet 
activation by the collagen receptor GPVI (activated with collagen-related peptide (CRP)), and 
PAR receptors (activated with thrombin). Such impact on Ca2+ release was minor compared 
to what happens in the case of CLEC-2 activation (Figure 3B). Finally, we explored the 
specific contribution of ADP and TXA2, individually, to CLEC-2 activation-mediated 
calcium release. Ca2+ release diminishes in the presence of apyrase or indomethacin, with a 































































higher impact of the former. Maximum inhibition of Ca2+ release following CLEC-2 
activation takes place when both inhibitors of secondary mediators are present at the same 
time (Figure 3C).
3.5. Contribution of secondary mediators to different steps essential for CLEC-2 
signalling 
In order to further elucidate the contribution of ADP and TXA2 at different points of the 
signalling pathway downstream of CLEC-2, we evaluated p-Tyr levels of residues that were 
identified in the analysis and are known to be essential for the catalytic activity of kinases Syk 
(p-Tyr525+526) and Src (p-Tyr419), and for PLCγ2 activity (p-Tyr759). To do so, we performed a 
western blot with protein samples obtained after activating the platelets in the presence or 
absence of apyrase and indomethacin under non aggregating conditions. In parallel, we just 
checked the aggregation profiles of platelets activated with Rhodcytin in the presence and 
absence of the secondary mediators inhibitors; as expected, the latter prevented aggregation 
(Figure 4A).
As it is shown in Figure 4B,C, phosphorylation of Syk on Tyr525/526, which is one of 
the primary events occurring upon CLEC-2 activation following hemITAM phosphorylation, 
is robustly increased in response to positive feedback by released ADP and TXA2. 
Nonetheless, CLEC-2 stimulation itself, in the presence of inhibitors of secondary mediators, 
led to a significant increase in phosphorylation of Syk Tyr525/526.
Robust phosphorylation of Src Tyr419, was also critically dependent on released ADP 
and TXA2. In this case, we also observed high levels of that phosphoprotein in resting (basal) 
platelets compared to the other two proteins analysed (Figure 4B,C). 
Finally, we also investigated the activation of PLCγ2, which enables Ca2+ release from 
intracellular stores and cytoskeleton remodelling process, so we evaluated its phosphorylation 































































on Tyr759. Optimal phosphorylation of PLCγ2 Tyr759 is only achieved when ADP and TXA2 
are not inhibited from exerting their positive feedback effects on CLEC-2 signalling (Figure 
4B,C).
One question that arises from the above data is whether the increase in tyrosine 
phosphorylation observed for the proteins validated is directly due to Rhodocytin-CLEC-2 
engagement with signalling reinforced by the secondary mediators’ positive feedback, or if 
such mediators could cause part of the increase by themselves. In order to clarify this issue, 
we activated platelets with ADP and arachidonic acid (AA), in comparison with Rhodocytin 
activation, in the absence of apyrase and indomethacin. Interestingly, ADP and AA are not 
able to induce an increase in the levels of Syk (p-Tyr525+526), Src (p-Tyr419), and PLCγ2 (p-
Tyr759), which confirms the differences observed in our analysis are mediated by CLEC-2 
activation (Fig. 5).
3.6. Tyrosine phosphorylation kinetic profiles show variations depending on the CLEC-2 
signalling protein analysed
To complete the signalling studies, we carried out a small scale kinetic analysis focusing on 
the three phosphoproteins mentioned above. As shown in Figure 6, tyrosine phosphorylation 
levels start to increase after 30 sec of platelet stimulation with 200 nM Rhodocytin and 
significant levels are still maintained after 5 minutes; however the kinetic profile is different 
depending on the protein. Thus, Syk, which plays a relevant role in early signalling events, is 
phosphorylated in Y525 and Y526 rapidly, reaching maximum levels after one minute and 
decreasing steadily after 90 sec. Regarding Src (p-Tyr419), basal levels are high compared with 
the other two proteins; nevertheless, there is an increase in phosphorylation levels following 
activation reaching the maximum after 1 min and maintaining such level for 3 min when it 































































starts to decrease gradually. Regarding PLCγ2 (p-Tyr759), maximum phosphorylation levels 
are also achieved between 1 and 3 min.
4. Discussion
The CLEC-2 receptor is known to mediate platelet activation through the stimulation of a 
phosphotyrosine signalling cascade that is triggered by phosphorylation of the tyrosine 
residue within its hemITAM5. In the present study, we aimed to analyse the phosphotyrosine 
proteome of CLEC-2-activated platelets. To do so, we performed an immunoaffinity 
enrichment of p-Tyr peptides in our samples, and we analysed them in an LTQ Orbitrap Velos 
mass spectrometer, an experimental tandem that allows high sensitivity on the identification 
of specific protein p-Tyr residues.
Results from our study emphasize the crucial synergism between the secondary 
mediators, ADP and TXA2, and CLEC-2 to induce a powerful activation of the receptor. To 
further explore this data, we evaluated the relevance of ADP and TXA2 in intracellular 
calcium release mediated by CLEC-2-Rhodocytin activation, and also by platelet activation 
with other agonists, such as CRP (GPVI agonist) and thrombin (PAR1/4 agonist). Our results 
clearly demonstrate the relevance of both ADP and TXA2 (together) to achieve full CLEC-2 
platelet activation, which does not happen in the case of GPVI or PAR1/4 activation. In 
addition, we also studied the phosphorylation levels of tyrosine sites that are crucial for the 
enzymatic activity of three proteins that are relevant for signal transduction upon CLEC-2 
activation: Syk p-Tyr525+526, Src p-Tyr419 and PLCγ2 p-Tyr759. Interestingly, we found that, 
although powerful platelet activation through the stimulatory effect of secondary mediators is 
essential for optimal Syk- kinase domain phosphorylation, rhodocytin stimulation of CLEC-2 
itself is sufficient to significantly increase Syk Tyr525+526 phosphorylation. In contrast, optimal 
phosphorylation of PLCγ2 Tyr759 is highly dependent on ADP and TXA2, indicating that the 































































initial steps of CLEC-2 signalling, including Syk phosphorylation, are not as dependent on 
ADP and TXA2 as downstream events. In resume, secondary mediators inhibitors are able to 
fully inhibit Src and  PLCγ2 tyrosine phosphorylation in the indicated residues, and can only 
partially inhibit Syk Tyr525+526.
To complement the above data, we also analysed the direct effect of ADP and AA to 
induce phosphorylation of Syk p-Tyr525+526, Src p-Tyr419 and PLCγ2 p-Tyr759, observing no 
effect, which indicates phosphorylation changes observed when activating platelets with 
rhodocytin in absence of apyrase and indomethacin are due to CLEC-2-activation and 
secondary mediators contribute only with a positive feedback to achieve full CLEC-2 tyrosine 
phosphorylation and signalling activation. Although it was previously suggested that the latter 
is mediated by Rac activation12, further research is needed to confirm the precise mechanism 
of this positive feedback in line with the present study. 
Complementary data on the three phosphoproteins mentioned above demonstrate 
differences in the kinetic profile of p-Tyr depending on the signalling protein analysed. For 
example, maximum phosphorylation levels of Syk on Tyr525+526 decrease faster than in the 
case of PLCγ2 Tyr759. The observed differences in the kinetic profile indicate that further 
kinetic studies by quantitative western blotting or proteomics are needed to have a more 
precise picture of the assembling of the CLEC-2 signalosome depicted in the present study.
Intriguingly, in the case of phosphorylation of Src Tyr419, which is located within the 
kinase domain responsible of Src-catalytic activity, the levels of basal samples were high 
compared to the other validated proteins, especially in the presence of secondary mediators 
(Figs. 4-6). This suggests the existence of a pool of active Src in platelets, reinforced by a 
basal release of secondary mediators. Further research is needed to explore this possibility; 
moreover, other SFKs besides Src, including Fyn, Lyn or Fgr, may contribute to signalling 
downstream of CLEC-2.































































Considering the above mentioned relevance of ADP and TXA2 in reinforcing CLEC-2 
signalling, as our aim was to obtain a broader picture of the biochemical events that are taking 
place in the signalling cascade downstream of CLEC-2 activation, we focused on the 
differentially regulated p-Tyr sites (FC ≥ 1.5) identified in “Rhod” samples (rhodocytin- 
activated in absence of inhibitors of secondary mediators) compared to unstimulated samples. 
We demonstrate differentially regulated p-Tyr residues for almost all the proteins known to 
participate in the CLEC-2 signalling pathway to date (Table 2). Interestingly, a number of 
those proteins were known to be phosphorylated upon CLEC-2 activation, but the specific 
tyrosine residues that undergo this modification were not described to date. Here, we have 
identified p-Tyr sites that are known to have great impact in signal transduction. CLEC-2 was 
found to be tyrosine phosphorylated on hemITAM motif -Tyr7-;5 phosphorylation of LAT 
Tyr220 was found to be up- regulated, which promotes its interaction with Grb2, Gads, and 
PIK3R122; Syk was phosphorylated at Tyr348 and Tyr352, both of which are essential for 
regulating Syk kinase activity, and at Tyr525 and Tyr526, required for catalytic activity23; the 
protein- tyrosine phosphatase SHP-1 was phosphorylated at Tyr536 and Tyr564, which have 
been implicated in regulating its activity  24; and CD148 was shown to be  phosphorylated on 
Tyr1311 and Tyr1320, previously reported to be  mediated by Src and Fyn25  and essential for 
SHP-1 interaction with CD148 SH2 domains. Moreover, the identification of several proteins 
tyrosine- phosphorylated on SH3, SH2, tyrosine- kinase, and phosphatase domains, as well as 
in ITIM motifs, highlights the potential relevance of the identified p-Tyr sites in mediating 
signal transduction upon CLEC-2 receptor activation (Table 2).
Furthermore, we have identified differentially regulated p-Tyr residues from proteins 
that have never been reported to play a role downstream of CLEC-2, but that are known to 
participate in regulating signal transduction in platelets and other blood cells. Some of these 
proteins have been described to interact and regulate the function of other known regulators of 































































CLEC-2 signalling. As a compendium of our proteomic data and the previous knowledge 
about protein interactions and functions, we have uncovered the more detailed picture of the 
CLEC-2 signalosome to date, represented in Figure 7, which includes key signalling proteins 
and their differentially regulated p-Tyr residues identified in our study. Interestingly, the set 
of proteins we show to be differentially- phosphorylated in our study suggests a delicate 
balance between stimulatory and inhibitory intracellular signals, which may be crucial for 
maintaining platelet activation without triggering an exacerbated response. Some of these 
novel phosphorylation sites and signalling proteins are likely to be clinically relevant, due to 
the potential interest of this receptor as a therapeutic target, since it seems to be crucial for 
thrombus stabilization, but not for haemostasis maintenance.   
Novel players on the CLEC-2 signalling cascade identified to be regulated by tyrosine- 
phosphorylation include the adapters Dok1 and Dok326, Nck1 and Nck227,28, and Crk- 
associated substrate (CAS) family members CASS4 and EFS29, among others (Table 2; 
Figure 7). Moreover, we report a number of up- regulated phosphorylated platelet kinases 
that were not previously described to participate in the CLEC-2 signalling cascade, but that 
are related to further signalling pathways, such as FAK, differentially phosphorylated at 
Tyr925, phosphorylation of which is mediated by FER allowing FAK interaction with Grb2 
and SHP-230; FES; and FGR31, among others (Table 2; Figure 7).
We also identified numerous p-Tyr residues differentially- regulated in proteins that 
are known to maintain platelet activation within physiological limits by exerting an inhibitory 
action during intracellular signalling processes. The most important effectors on regulating 
signal transduction upon ITAM-receptor activation are the immunoreceptor tyrosine-based 
inhibition motif (ITIM)-containing receptors. Tyrosine-phosphorylation of these domains 
provides docking sites for SH2 domain- containing phosphatases, such as SHIP1, SHP-1 and 
SHP-2, all of which were found to contain differentially regulated p-Tyr residues in our study 































































(Table 2; Figure 7), localizing the phosphatases in close proximity with ITAM-containing 
receptors that can then dephosphorylate and inactivate32. G6b-B is an ITIM-containing 
membrane protein that has been already reported to participate in CLEC-2 mediated 
signalling33,34, and that we found to be further phosphorylated on ITIM Tyr211 and Tyr237 upon 
rhodocytin stimulation. Moreover, we identified up-regulated tyrosine- phosphorylated 
residues for the other two known platelet ITIM-containing receptors, PECAM-1 and TLT-1. 
PECAM-1 was found to be phosphorylated on Tyr663, Tyr690, and Tyr713, the last two located 
on the ITIM domain of the protein, and both known to be phosphorylated by Lyn35. PECAM-
1 was reported to negatively regulate platelet GPVI-activation, as a feedback mechanism to 
limit thrombus growth, through the binding of its ITIM domains to SHP-236,37. Interestingly, 
PECAM-1 is thought to exert its inhibitory activity by an additional mechanism, consisting in 
the recruitment of PIK3R1 regulatory subunit of PI3K that we also found to be differentially 
tyrosine phosphorylated, through its interaction with SHP-2, negatively regulating the LAT 
signalosome by decreasing the interaction of LAT, Gab1 and PIK3R138. Gab1 is another 
protein that we are reporting to participate in the CLEC-2 signalling pathway for the first 
time, since we found differentially regulated p-Tyr residues of this protein following 
stimulation with rhodocytin. Gab1 is an adaptor protein that regulates signal transduction 
downstream of PI3K by directly interacting with this kinase. Finally, phosphorylation of 
Tyr245 in the atypical ITIM-containing receptor TLT-1 was found to be up-regulated in 
rhodocytin-stimulated platelets.  This residue was not previously reported to undergo 
phosphorylation, which may regulate downstream signalling39. Another kinase identified, 
Csk, phosphorylates the C-terminal tyrosine of SFKs inactivating them, a mechanism that is 
in part compensated by the phosphatase CD148, previously reported to participate in CLEC-2 
downstream signalling events40,41, and phosphorylation of which we found to be up-regulated 
in our proteomic analysis (Table 2; Figure 7). 































































Of the phosphatases found to be phosphorylated in rhodocytin-stimulated platelets, 
CD148, SHP-1, SHP-2, SHIP1, and PTP1B were previously reported to participate in the 
CLEC-2 signalling14,42-44. In addition, we also found p-Tyr residues within SHIP2, PTPRA, 
PTN18, and PTN12 (Table 2; Figure 7) to be up-regulated, suggesting these phosphatases 
may also contribute to the regulation of CLEC-2 signalling. Further, another protein that was 
reported to negatively regulate platelet signalling, and more precisely GPVI- mediated 
signalling downstream PI3K, is the adapter DAPP145. Interestingly, we found 
phosphorylation of Tyr139 within DAPP1 to be up-regulated, which is required for its 
interaction with PLCγ2 and protein function46,47.  
In conclusion, we have performed the most extensive tyrosine phosphoproteomic 
analysis of the CLEC-2 signalling pathway in platelets to date. We identified differentially 
regulated p-Tyr sites relevant for the activity of known as well as novel proteins in the CLEC-
2 signalling cascade. We also demonstrated a crucial role of AA and ADP (together) to 
achieve full CLEC-2-mediated platelet activation, and phosphorylation of relevant tyr sites in 
CLEC-2 signalling proteins. We also show that the kinetic profiles of phosphorylation of key 
tyrosine residues in some relevant CLEC-2 signalling proteins - such as Syk (Tyr525+526), Src 
(Tyr419) and PLCγ2 (Tyr759) - vary slightly depending on the precise phosphoprotein analysed, 
which provides clues on the role of each protein in the pathway. Overall, we believe that our 
study provides significant insights into the intracellular events that take place following 
CLEC-2 activation in platelets, contributing to elucidate in detail the CLEC-2 signalosome.
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Tables
Table 1. Results from LC-MS/MS analysis.
CONTITION P-TYR PEPTIDES P-TYR SITES P-TYR PROTEINS
Total 757 466 264
Basal 374 288 187
Rhod inh 421 313 198
Rhod 688 458 258
Rhod inh: rhodocytin- activated in presence of secondary mediators’ inhibitors; Rhod: 
rhodocytin- activated in absence of secondary mediators’ inhibitors.































































Table 2. Tyrosine- phosphorylation sites of relevant signalling proteins identified in “Rhod” vs. 
“Basal” samples with a fold change (FC) ≥ 1.5.
Uniprot code Protein names P-Site FC Relevant Domain
Adaptor/Scaffold
ABI1_HUMAN* Abl interactor 1 (ABI1) Y213 ∞
Y455 ∞ SH3
BANK1_HUMAN* B-cell scaffold protein with ankyrin repeats (BANK1) Y443 ∞
Y737 3.00
CASS4_HUMAN* Cas scaffolding protein family member 4 (CASS4) Y350 ∞
Y174 ∞
Y195 ∞





DAPP1_HUMAN* Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide (DAPP1) Y139 3.00
DOK1_HUMAN* Docking protein 1 (DOK1) Y377 ∞ Pro rich
Y296 ∞ Pro rich
Y362+Y377 ∞ Pro rich
Y409 3.50 Pro rich
Y449 1.50
DOK2_HUMAN Docking protein 2 (DOK2) Y139 ∞
Y402 ∞
DOK3_HUMAN* Docking protein 3 (DOK3) Y398 2.44 Pro rich
EFS_HUMAN* Embryonal Fyn-associated substrate (EFS) Y163 ∞ Pro rich
FYB1_HUMAN FYN-binding protein 1 (FYB1; ADAP; FYB; SLAP130) Y387 5.00
Y757 3.00 SH3
GAB1_HUMAN* GRB2-associated-binding protein 1 (GAB1) Y659 ∞
GRAP2_HUMAN GRB2-related adapter protein 2 (GRAP2; GADS) Y207 ∞
Y45 3.00 SH3
GRB2_HUMAN Growth factor receptor-bound protein 2 (GRB2) Y209 ∞ SH3
LAT_HUMAN Linker for activation of T-cells family member 1 (LAT) Y45 4.67
Y220 3.40
LCP2_HUMAN Lymphocyte cytosolic protein 2 (LCP2; SLP-76; SLP76) Y532 ∞
Y39 2.00
NCK1_HUMAN* Cytoplasmic protein NCK1 (NCK1; NCK) Y105 1.56































































Uniprot code Protein names P-Site FC Relevant Domain
Adaptor/Scaffold
NCK2_HUMAN* Cytoplasmic protein NCK2 (NCK2) Y50 ∞ SH3
Y251 ∞ SH3
Y110 2.91
NTAL_HUMAN* Linker for activation of T-cells family member 2 (LAT2; NTAL) Y136 ∞
Y58 ∞
PARD3_HUMAN* Partitioning defective 3 homolog (PARD3; PAR3) Y719 ∞
Y1080 4.00





REPS2_HUMAN* RalBP1-associated Eps domain-containing protein 2 (REPS2) Y558 ∞
SKAP2_HUMAN Src kinase-associated phosphoprotein 2 (SKAP2) Y169 ∞
Y334 2.00 SH3
Y151/Y152 -2.00
SPN90_HUMAN* NCK-interacting protein with SH3 domain (NCKIPSD; SPIN90) Y161 -∞
STAM2_HUMAN* Signal transducing adapter molecule 2 (STAM2) Y374 2.00 ITAM
VAV_HUMAN Proto-oncogene vav (VAV1; VAV) Y844 ∞
Y791 ∞ SH3
Y110 11.00
WASP_HUMAN* Wiskott-Aldrich syndrome protein (WAS) Y212 ∞
Y291 3.33
WIPF1_HUMAN* WAS/WASL-interacting protein family member 1 (WIPF1) Y455 ∞
WIPF2_HUMAN* WAS/WASL-interacting protein family member 2 (WIPF2) Y400 ∞
Kinase
ABL2_HUMAN* Tyrosine-protein kinase ABL2 (ABL2) Y439 ∞ Tyr- kinase
ACK1_HUMAN* Activated CDC42 kinase 1 (TNK2; ACK1) Y518 2.00
Y827 -1.67




CSK_HUMAN* Tyrosine-protein kinase CSK (CSK) Y18 ∞ SH3































































Uniprot code Protein names P-Site FC Relevant Domain
Kinase
FAK1_HUMAN* Focal adhesion kinase 1 (PTK2; FAK; FAK1) Y925 2.50
FER_HUMAN Tyrosine-protein kinase Fer (FER) Y402 ∞
Y714 3.33 Tyr- kinase
FES_HUMAN* Tyrosine-protein kinase Fes/Fps (FES; FPS) Y513 ∞
Y713 5.00 Tyr- kinase
FGR_HUMAN* Tyrosine-protein kinase Fgr (FGR; SRC2) Y208/Y209 ∞ SH2
FYN_HUMAN Tyrosine-protein kinase Fyn (FYN) Y213 ∞ SH2
JAK2_HUMAN* Tyrosine-protein kinase JAK2 (JAK2) Y570 1.83 Tyr- kinase
KALRN_HUMAN* Kalirin (KALRN) Y2265 4.00
KGP1_HUMAN* cGMP-dependent protein kinase 1 (PRKG1) Y336 ∞
KPCD_HUMAN Protein kinase C delta type (PRKCD) Y64 ∞
Y313 3.00
Y334 2.40




Y525+Y526 3.50 Tyr- kinase
Y526 1.50 Tyr- kinase
LYN_HUMAN Tyrosine-protein kinase Lyn (LYN) Y306 4.00 Kinase
MK01_HUMAN Mitogen-activated protein kinase 1 (MAPK1; ERK2) Y187 6.00 Tyr- kinase
MK03_HUMAN Mitogen-activated protein kinase 3 (MAPK3; ERK1) Y204 ∞ Kinase
MK08_HUMAN Mitogen-activated protein kinase 8 (MAPK8; JNK1) Y185 ∞ Kinase
MK09_HUMAN Mitogen-activated protein kinase 9 (MAPK9; JNK2) Y185 1.82 Kinase
MK12_HUMAN Mitogen-activated protein kinase 12 (MAPK12; ERK6) Y185 6.00 Kinase
MK14_HUMAN Mitogen-activated protein kinase 14 (MAPK14; CSBP) Y182 2.15 Kinase
MRCKB_HUMAN* Serine/threonine-protein kinase MRCK beta (CDC42BPB) Y1638 3.00
P85A_HUMAN Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1; GRB1) Y467 2.00
PI4KA_HUMAN* Phosphatidylinositol 4-kinase alpha (PI4KA; PIK4) Y1154 -4.00
ROCK2_HUMAN* Rho-associated protein kinase 2 (ROCK2) Y722 5.00
Y450 5.00
SRC_HUMAN Proto-oncogene tyrosine-protein kinase Src (SRC; SRC1) Y187 -2.00 SH2































































Uniprot code Protein names P-Site FC Domain
Phosphatase
PTN1_HUMAN Tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP1B) Y46 4.00 Phosphatase
PTN11_HUMAN Tyrosine-protein phosphatase non-receptor type 11 (PTPN11; SHP-2) Y584 1.57
PTN12_HUMAN* Tyrosine-protein phosphatase non-receptor type 12 (PTPN12; PTPG1) Y64 ∞ Phosphatase
PTN18_HUMAN* Tyrosine-protein phosphatase non-receptor type 18 (PTPN18) Y426 ∞
Y389 2.50




SHIP1_HUMAN Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (INPP5D; SHIP; SHIP1) Y1022 ∞ Pro rich










CLC1B_HUMAN C-type lectin domain family 1 member B (CLEC1B; CLEC2) Y7 ∞ ITAM
FCERG_HUMAN* High affinity immunoglobulin epsilon receptor subunit gamma (FCER1G) Y58 2.00 ITAM
FCG2A_HUMAN* Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) Y304 3.00
G6B_HUMAN Megakaryocyte and platelet inhibitory receptor G6b (MPIG6B; G6B; G6B-B) Y211 4.33 ITIM
Y237 2.00 ITIM
PTPRA_HUMAN* Receptor-type tyrosine-protein phosphatase alpha (PTPRA; PTPA) Y798 2.00
PTPRJ_HUMAN Receptor-type tyrosine-protein phosphatase eta (PTPRJ; CD148) Y1311+Y1320 ∞
Y1311 9.00
JAM1_HUMAN* Junctional adhesion molecule A (JAM-A) Y280 -3.00
TRML1_HUMAN* Trem-like transcript 1 protein (TLT-1) Y245 3.06 Pro rich































































Uniprot code Protein names P-Site FC Domain
Small GTPase
RAB13_HUMAN* Ras-related protein Rab-13 (RAB13) Y5 ∞
RAB1B_HUMAN* Ras-related protein Rab-1B (RAB1B) Y5 ∞
RAN_HUMAN* GTP-binding nuclear protein Ran (RAN) Y39 1.50
GAP
ARAP1_HUMAN* Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 (ARAP1) Y737 3.50
IQGA2_HUMAN* Ras GTPase-activating-like protein IQGAP2 (IQGAP2) Y93 ∞
RASA1_HUMAN* Ras GTPase-activating protein 1 (RASA1) Y615 2.00
RASA3_HUMAN* Ras GTPase-activating protein 3 (RASA3) Y66 ∞
RHG18_HUMAN* Rho GTPase-activating protein 18 (ARHGAP18) Y41 4.00
RHG35_HUMAN* Rho GTPase-activating protein 35 (ARHGAP35) Y1087 ∞
Y1105 1.75
GDI
GDIR2_HUMAN* Rho GDP-dissociation inhibitor 2 (ARHGDIB) Y130 -∞
Y24 ∞
GEF










GRP2_HUMAN* RAS guanyl-releasing protein 2 (RASGRP2) Y523 -2.00
Other
LY66F_HUMAN* Lymphocyte antigen 6 complex locus protein G6f (LY6G6F; G6F) Y281 4.50
PECA1_HUMAN* Platelet endothelial cell adhesion molecule (PECAM-1) Y663 3.67
Y690 ∞ ITIM
A positive fold change indicates that the variation is favourable to “Rhod” samples (rhodocytin- activated in 
absence of secondary mediators’ inhibitors), and a negative fold change indicates that the variation is 
favourable to basal samples. Fold changes were calculated as the quotient of the total number of PSMs that led 
to the identification of the protein p-site. GAP: GTPase-activating protein; GDI: GDP dissociation inhibitor; 
GEF: Guanine nucleotide exchange factor. ∞ means infinity.
* Means that the protein was not previously reported to participate in CLEC-2 signalling pathway.
































































Figure 1. Experimental workflow. Schematic representation of the methodology 
applied and the equipment employed in this study.
Figure 2. P-Tyr peptides, and p-Tyr sites identified by LC-MS/MS. Function of 
proteins with differentially regulated p-Tyr sites in CLEC-2-activated platelets. 
Venn diagrams represent the total number of p-Tyr peptides (A), and the corresponding 
p-Tyr sites (B), that were identified in each analysed condition. C) Functions of proteins 
that were identified with differentially regulated p-Tyr sites in CLEC-2-activated vs. 
basal platelets. Charts represent protein functions distribution (FC ≥ 1.5).
Figure 3. Ca2+ mobilization following CLEC-2 activation is dependent on 
secondary mediators. A) Secondary mediators play a fundamental role in CLEC-2-
mediated Ca2+ release induced by platelet activation with Rhodcytin. B) Secondary 
mediators are needed for a full platelet activation induced by Rhodocytin, in contrast 
with what occurs in the case of platelet activation with CRP or thrombin. C) Both ADP 
and TXA2 together are needed for full CLEC-2 activation. Rhod, Rhodocytin; CRP, 
collagen-related peptide; THR, thrombin. All measurements were done in triplicate 
(biological replicates). For further experimental details please see section 2.6.
Figure 4. Contribution of ADP and TXA2 to phosphorylation of relevant tyrosine 
residues in Src, Syk, and PLC2 downstream of CLEC-2. A) Aggregation profile of 
platelets stimulated with 200nM rhodocytin in absence and presence of secondary 
mediators inhibitors (2U/mL apyrase and indomethacin 10µM). Representative western 
blot images (B), and densitometry graphs (C), representing tyrosine phosphorylation 
levels of Src p-Tyr419, Syk p-Tyr525+526, and PLCγ2 p-Tyr759. ** p< 0.01 (RM one way 































































Anova with Tukey´s post-hoc multiple comparisons). Experiments were done with 
samples obtained from 4 different healthy donors (biological replicates).
Figure 5. ADP and arachidonic acid do not induce tyrosine phosphorylation of Src, 
Syk, and PLC2 in the same residues CLEC-2 activation does. A) Aggregation 
profile of platelets stimulated with 200nM rhodocytin, 10 µM ADP, and 100 µM AA.  
Representative western blot images (B) and densitometry graphs (C) showing tyrosine 
phosphorylation levels of Src p-Tyr419, Syk p-Tyr525+526, and PLCγ2 p-Tyr759 in 
response to Rhodocytin and AA+ADP. Comparisons were between each stimulus and 
its respective control. ** p< 0.01 (paired Student´s t-test). Experiments were done with 
samples obtained from 4 different healthy donors (biological replicates).
Figure 6. Kinetic studies on essential tyrosine residues in Src, Syk, and PLC2 
downstream of CLEC-2 point out differences in the phosphorylation pattern. 
Representative western blot images (A), and densitometry graphs (B) showing tyrosine 
phosphorylation profiles of Src p-Tyr419, Syk p-Tyr525+526, and PLCγ2 p-Tyr759 
following platelet activation with rhodocytin for 30s, 60s, 120s, 180s and 300s. For 
statistics, comparisons were always between each activation time point and basal 
(control platelets). *p<0.05, ** p < 0.01, and *** p < 0.001 (paired Student´s t-test). 
Experiments were done with samples obtained from 4 different healthy donors 
(biological replicates).
Figure 7. The CLEC-2 signalling pathway in platelets: solving the puzzle. New 
proposal for the platelet CLEC-2 signalling cascade in which relevant signalling 
proteins and their corresponding differentially regulated p-Tyr sites identified in the 
present study are highlighted. This figure only includes those Tyr residues that were 
identified as differentially regulated in the present proteomic study (Fold change ≥ 1.5). 































































Further information on how the information to build the figure was retrieved can be 
found in section 2.4.
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